Their extraordinary expertise and background will help guide Nanogea's research and development in the foreseeable future as we expedite our development effort to commercialize our first clinical application for CML (Chronic Myelogeous Leukemia) detection, based on our proprietary NanoCone™ chemistry and NE-AFM™ platform.
Westlake Village, Calif. (PRWEB) October 9, 2009
Nanogea, a nano-biotech company focused on commercializing the industry's most sensitive single molecular detection platform, is pleased to announce today that Dr. C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board.
Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey presently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to expose disease mechanisms. He is a former founding Director and CEO of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life science companies. Dr. Caskey is a former SVP for Res. at Merck and Trustee and President of the Merck Genome Res. Inst. as well as an Ex-Chief of Section of Medical Genetics and Professor of Medicine and Biochemistry, Baylor College of Medicine. He sits on the boards of Essex Woodlands Health Ventures, Luminex, Odyssey Thera, En Vivo, Metabolon, Genome Canada, LabCorp. of America, and Vice Chair of Genome Canada. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science of Texas (President of TAMEST 2004-05), a member of the National Academy of Sciences, and the Institute of Medicine. Dr. Caskey received his medical doctorate from Duke University. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases, and Molecular Diagnostics.
Dr. Saul Tendler is Pro-Vice-Chancellor, Professor of Biophysical Chemistry and Head of the School of Pharmacy, University of Nottingham. His expertise is in the field of biophysical chemistry, with a particular focus on analysis of biomolecular systems and their interactions. Dr. Tendler is a Fellow of the Royal Society of Chemistry, and was designated a Fellow of the Royal Pharmaceutical Society of Great Britain in 2000. Dr. Tendler received his Ph.D. from the University of Aston and his Bachelors of Science (First Class Honours) in Pharmacy at the University of Manchester.
"We are delighted to have a distinguished panel of advisors such as Drs. Caskey and Tendler," said Mr. David Sun, President and CEO of Nanogea, "Their extraordinary expertise and background will help guide Nanogea's research and development in the foreseeable future as we expedite our development effort to commercialize our first clinical application for CML (Chronic Myelogeous Leukemia) detection, based on our proprietary NanoCone™ chemistry and NE-AFM™ platform."
Nanogea, a nano-biotech company located in Westlake Village California, is focused on commercializing the industry's most sensitive genomic and proteomic detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force Microscopy (NE-AFM™ ) technology. The Company is utilizing its technology to push the genetic and protein detection limit to the single molecular level, thus greatly improving the sensitivity and accuracy of disease diagnosis, prognosis, treatment, and monitoring as well as drug discovery research. To learn more about our pioneering technology, visit http://www.nanogea.com.
5716 Corsa Avenue, Suite 201
Westlake Village, CA 91362.
Phone: (818) 889-0538 Fax: (818) 889-0816